No Data
No Data
Vistagen Awarded Mental Health America's Platinum Bell Seal for Workplace Mental Health for the Second Consecutive Year
Mental Health America's highest national certification enhances Vistagen's ongoing efforts to promote mental health throughout the U.S. Vistagen (NASDAQ:VTGN), a clinical-stage neuroscience-focused biopharmaceutical
Vistagen Therapeutics Full Year 2024 Earnings: EPS Beats Expectations
Earnings Call Summary | VistaGen Therapeutics(VTGN.US) Q4 2024 Earnings Conference
The following is a summary of the Vistagen Therapeutics, Inc. (VTGN) Q4 2024 Earnings Call Transcript:Financial Performance:Reported a significant reduction in R&D expenses to $20 million for FY 2024
VistaGen Therapeutics | 10-K: Annual report
VistaGen Therapeutics GAAP EPS of -$1.52 Misses by $1.16, Revenue of $1.06M Beats by $0.86M
Vistagen Reports FY24 Net Loss Of $(29.4)M Vs $(59.2)M Last Year
Cash and cash equivalents were $119.2 million as of March 31, 2024.